<p>Celldex Therapeutics, Inc. (NASDAQ:CLDX - 获取免费报告) 的股价在周一交易前跳涨，此前巴克莱将该股评级从减持上调至增持。该股此前收于 34.55 美元，但开盘价为 35.79 美元。巴克莱现在对该股的目标价为 45.00 美元，高于之前的 24.00 美元目标价。Celldex Therapeutics 的股票最后交易价格为 34.6910 美元，成交量为 215,711 股。</p>
<p>获取 <strong>Celldex Therapeutics</strong> 的提醒：</p>
<p>其他几位股票研究分析师最近也对 CLDX 发布了报告。Stifel Nicolaus 在 2 月 26 日的研究报告中重申了 “买入” 评级，并将 Celldex Therapeutics 的目标价上调至 68.00 美元（高于 58.00 美元）。高盛集团在 3 月 2 日的研究报告中将 Celldex Therapeutics 的目标价从 30.00 美元提高至 34.00 美元，并给予该公司 “中性” 评级。Wolfe Research 在 3 月 23 日的研究报告中将 Celldex Therapeutics 的评级从 “同行表现” 上调至 “跑赢大盘”，并为该公司设定了 44.00 美元的目标价。最后，Weiss Ratings 在 1 月 21 日的研究报告中重申了对 Celldex Therapeutics 的 “卖出（d-）” 评级。一位投资分析师给予该股 “强烈买入” 评级，九位分析师给予 “买入” 评级，一位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 46.36 美元。</p>
<p><strong>获取我们关于 Celldex Therapeutics 的最新研究报告</strong></p>
<h2>机构资金流入和流出</h2>
<p>一些机构投资者最近修改了对 CLDX 的持股。Aster Capital Management DIFC Ltd 在第三季度购买了 Celldex Therapeutics 的新股份，价值约为 26,000 美元。Wilmington Savings Fund Society FSB 在第三季度收购了 Celldex Therapeutics 的新股份，价值约为 42,000 美元。Russell Investments Group Ltd.在第二季度将其在 Celldex Therapeutics 的持股增加了 27.6%。Russell Investments Group Ltd.目前拥有 2,315 股该生物制药公司的股票，价值 47,000 美元，此前在上个季度又购买了 501 股。Quantbot Technologies LP 在第三季度收购了 Celldex Therapeutics 的新股份，价值约为 63,000 美元。最后，Strs Ohio 在第三季度收购了 Celldex Therapeutics 的新股份，价值约为 75,000 美元。</p>
<h2>Celldex Therapeutics 股价上涨 0.3%</h2>
<p>该公司的市值为 23.1 亿美元，市盈率为-8.91，贝塔值为 1.19。该公司的 50 日移动平均线为 29.33 美元，200 日移动平均线为 27.29 美元。</p>
<p>Celldex Therapeutics (NASDAQ:CLDX - 获取免费报告) 最近于 2 月 25 日发布了其财报。这家生物制药公司报告本季度每股收益为（1.22 美元），低于分析师的共识预期（1.00 美元）22 美分。该公司本季度的收入为 12 万美元，而分析师的预期为 153 万美元。研究分析师预测 Celldex Therapeutics, Inc.在当前年度将发布-2.48 美元的每股收益。</p>
<h2>Celldex Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Celldex Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于癌症和其他严重疾病的靶向免疫疗法的发现和开发。该公司的研究平台利用新型抗体和疫苗技术，旨在激活患者的免疫系统，特别强调肿瘤学和神经学适应症。Celldex 的产品线包括单克隆抗体和生物制剂，旨在调节免疫反应或提供靶向细胞毒性活性。</p>
<p>Celldex 的主要产品候选之一是 glembatumumab vedotin，这是一种针对糖蛋白 NMB（gpNMB）的抗体 - 药物偶联物，用于治疗某些乳腺癌和皮肤癌。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们认为比 Celldex Therapeutics 更好的股票</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Celldex Therapeutics 吗？</h2>
<p>在你考虑 Celldex Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Celldex Therapeutics 并不在名单上。</p>
<p>虽然 Celldex Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

塞德斯医疗

<p>Celldex Therapeutics（纳斯达克代码：CLDX）股价在巴克莱将其评级从 “减持” 上调至 “增持” 后出现跳空上涨，目标价从 24 美元提高至 45 美元。该股以 35.79 美元开盘，较前一交易日的 34.55 美元上涨。其他分析师也给予了积极评级，普遍评级为 “适度买入”，平均目标价为 46.36 美元。该公司报告的季度每股收益为（1.22 美元），未达到预期，市值为 23.1 亿美元。Celldex 专注于开发针对癌症和严重疾病的靶向免疫疗法</p>

<p>Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report)'s stock price gapped up prior to trading on Monday after Barclays upgraded the stock from an underweight rating to an overweight rating. The stock had previously closed at $34.55, but opened at $35.79. Barclays now has a $45.00 price target on the stock, up from their previous price target of $24.00. Celldex Therapeutics shares last traded at $34.6910, with a volume of 215,711 shares trading hands.</p>
<div class="lb-trans"><p>Celldex Therapeutics, Inc. (NASDAQ:CLDX - 获取免费报告) 的股价在周一交易前跳涨，此前巴克莱将该股评级从减持上调至增持。该股此前收于 34.55 美元，但开盘价为 35.79 美元。巴克莱现在对该股的目标价为 45.00 美元，高于之前的 24.00 美元目标价。Celldex Therapeutics 的股票最后交易价格为 34.6910 美元，成交量为 215,711 股。</p>
</div><p>Get <strong>Celldex Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Celldex Therapeutics</strong> 的提醒：</p>
</div><p>Several other equities research analysts also recently issued reports on CLDX. Stifel Nicolaus reaffirmed a &#34;buy&#34; rating and issued a $68.00 price target (up from $58.00) on shares of Celldex Therapeutics in a research report on Thursday, February 26th. The Goldman Sachs Group increased their target price on shares of Celldex Therapeutics from $30.00 to $34.00 and gave the company a &#34;neutral&#34; rating in a research note on Monday, March 2nd. Wolfe Research upgraded shares of Celldex Therapeutics from a &#34;peer perform&#34; rating to an &#34;outperform&#34; rating and set a $44.00 target price for the company in a research note on Monday, March 23rd. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Celldex Therapeutics in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $46.36.</p>
<div class="lb-trans"><p>其他几位股票研究分析师最近也对 CLDX 发布了报告。Stifel Nicolaus 在 2 月 26 日的研究报告中重申了 “买入” 评级，并将 Celldex Therapeutics 的目标价上调至 68.00 美元（高于 58.00 美元）。高盛集团在 3 月 2 日的研究报告中将 Celldex Therapeutics 的目标价从 30.00 美元提高至 34.00 美元，并给予该公司 “中性” 评级。Wolfe Research 在 3 月 23 日的研究报告中将 Celldex Therapeutics 的评级从 “同行表现” 上调至 “跑赢大盘”，并为该公司设定了 44.00 美元的目标价。最后，Weiss Ratings 在 1 月 21 日的研究报告中重申了对 Celldex Therapeutics 的 “卖出（d-）” 评级。一位投资分析师给予该股 “强烈买入” 评级，九位分析师给予 “买入” 评级，一位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 46.36 美元。</p>
</div><p><strong>Get Our Latest Research Report on Celldex Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Celldex Therapeutics 的最新研究报告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of institutional investors have recently modified their holdings of CLDX. Aster Capital Management DIFC Ltd bought a new position in shares of Celldex Therapeutics in the third quarter valued at approximately $26,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Celldex Therapeutics in the third quarter valued at approximately $42,000. Russell Investments Group Ltd. increased its holdings in shares of Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company's stock valued at $47,000 after purchasing an additional 501 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Celldex Therapeutics in the third quarter valued at approximately $63,000. Finally, Strs Ohio acquired a new stake in shares of Celldex Therapeutics in the third quarter valued at approximately $75,000.</p>
<div class="lb-trans"><p>一些机构投资者最近修改了对 CLDX 的持股。Aster Capital Management DIFC Ltd 在第三季度购买了 Celldex Therapeutics 的新股份，价值约为 26,000 美元。Wilmington Savings Fund Society FSB 在第三季度收购了 Celldex Therapeutics 的新股份，价值约为 42,000 美元。Russell Investments Group Ltd.在第二季度将其在 Celldex Therapeutics 的持股增加了 27.6%。Russell Investments Group Ltd.目前拥有 2,315 股该生物制药公司的股票，价值 47,000 美元，此前在上个季度又购买了 501 股。Quantbot Technologies LP 在第三季度收购了 Celldex Therapeutics 的新股份，价值约为 63,000 美元。最后，Strs Ohio 在第三季度收购了 Celldex Therapeutics 的新股份，价值约为 75,000 美元。</p>
</div><h2>Celldex Therapeutics Stock Up 0.3%</h2>
<div class="lb-trans"><h2>Celldex Therapeutics 股价上涨 0.3%</h2>
</div><p>The firm has a market cap of $2.31 billion, a price-to-earnings ratio of -8.91 and a beta of 1.19. The business's fifty day moving average is $29.33 and its two-hundred day moving average is $27.29.</p>
<div class="lb-trans"><p>该公司的市值为 23.1 亿美元，市盈率为-8.91，贝塔值为 1.19。该公司的 50 日移动平均线为 29.33 美元，200 日移动平均线为 27.29 美元。</p>
</div><p>Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing analysts' consensus estimates of ($1.00) by ($0.22). The business had revenue of $0.12 million for the quarter, compared to analysts' expectations of $1.53 million. Research analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.</p>
<div class="lb-trans"><p>Celldex Therapeutics (NASDAQ:CLDX - 获取免费报告) 最近于 2 月 25 日发布了其财报。这家生物制药公司报告本季度每股收益为（1.22 美元），低于分析师的共识预期（1.00 美元）22 美分。该公司本季度的收入为 12 万美元，而分析师的预期为 153 万美元。研究分析师预测 Celldex Therapeutics, Inc.在当前年度将发布-2.48 美元的每股收益。</p>
</div><h2>Celldex Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Celldex Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company's research platforms leverage novel antibody and vaccine technologies designed to engage the patient's immune system, with a particular emphasis on oncology and neurologic indications. Celldex's pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.</p>
<div class="lb-trans"><p>Celldex Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于癌症和其他严重疾病的靶向免疫疗法的发现和开发。该公司的研究平台利用新型抗体和疫苗技术，旨在激活患者的免疫系统，特别强调肿瘤学和神经学适应症。Celldex 的产品线包括单克隆抗体和生物制剂，旨在调节免疫反应或提供靶向细胞毒性活性。</p>
</div><p>Among Celldex's lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.</p>
<div class="lb-trans"><p>Celldex 的主要产品候选之一是 glembatumumab vedotin，这是一种针对糖蛋白 NMB（gpNMB）的抗体 - 药物偶联物，用于治疗某些乳腺癌和皮肤癌。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Celldex Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Celldex Therapeutics 更好的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Celldex Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Celldex Therapeutics 吗？</h2>
</div><p>Before you consider Celldex Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Celldex Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Celldex Therapeutics 并不在名单上。</p>
</div><p>While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Celldex Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up  Following Analyst Upgrade

Market Beat

巴克莱银行

Stifel Financial

高盛

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

GS Hldg R

塞德斯医疗（NASDAQ:CLDX）股票在分析师上调评级后出现跳空高开